UY38473A - Formulaciones farmacéuticas para una administración subcutánea - Google Patents
Formulaciones farmacéuticas para una administración subcutáneaInfo
- Publication number
- UY38473A UY38473A UY0001038473A UY38473A UY38473A UY 38473 A UY38473 A UY 38473A UY 0001038473 A UY0001038473 A UY 0001038473A UY 38473 A UY38473 A UY 38473A UY 38473 A UY38473 A UY 38473A
- Authority
- UY
- Uruguay
- Prior art keywords
- subcutaneous administration
- pharmaceutical formulations
- monophosphate
- compositions
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composiciones de 4’-monofosfato de levodopa y 4’-monofosfato de carbidopa que tienen una relación peso en peso de aproximadamente 20:1 y métodos para tratar el mal de Parkinson y condiciones asociadas mediante la administración subcutánea de dichas composiciones.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862767546P | 2018-11-15 | 2018-11-15 | |
US201962843945P | 2019-05-06 | 2019-05-06 | |
US201962863101P | 2019-06-18 | 2019-06-18 | |
US201962863113P | 2019-06-18 | 2019-06-18 | |
US201962863093P | 2019-06-18 | 2019-06-18 | |
US201962898214P | 2019-09-10 | 2019-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38473A true UY38473A (es) | 2020-06-30 |
Family
ID=68835352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038473A UY38473A (es) | 2018-11-15 | 2019-11-15 | Formulaciones farmacéuticas para una administración subcutánea |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200155578A1 (es) |
EP (1) | EP3880210A1 (es) |
JP (1) | JP2022507528A (es) |
KR (1) | KR20210091139A (es) |
CN (1) | CN113015531A (es) |
AU (1) | AU2019379806A1 (es) |
BR (1) | BR112021009353A2 (es) |
CA (1) | CA3117983A1 (es) |
IL (1) | IL282842A (es) |
MX (1) | MX2021005776A (es) |
SG (1) | SG11202104499RA (es) |
TW (1) | TW202031265A (es) |
UY (1) | UY38473A (es) |
WO (1) | WO2020102628A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2024005084A (es) | 2021-10-27 | 2024-05-14 | Abbvie Inc | Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3116475T3 (da) | 2014-03-13 | 2020-12-07 | Neuroderm Ltd | Dopa-decarboxylasehæmmersammensætninger |
EP3209302B1 (en) | 2014-10-21 | 2019-04-24 | AbbVie Inc. | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease |
US10757941B2 (en) | 2016-07-22 | 2020-09-01 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018154447A1 (en) | 2017-02-21 | 2018-08-30 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
-
2019
- 2019-11-15 BR BR112021009353A patent/BR112021009353A2/pt unknown
- 2019-11-15 KR KR1020217013385A patent/KR20210091139A/ko active Search and Examination
- 2019-11-15 AU AU2019379806A patent/AU2019379806A1/en active Pending
- 2019-11-15 JP JP2021526553A patent/JP2022507528A/ja active Pending
- 2019-11-15 UY UY0001038473A patent/UY38473A/es unknown
- 2019-11-15 TW TW108141664A patent/TW202031265A/zh unknown
- 2019-11-15 MX MX2021005776A patent/MX2021005776A/es unknown
- 2019-11-15 CA CA3117983A patent/CA3117983A1/en active Pending
- 2019-11-15 CN CN201980074883.1A patent/CN113015531A/zh active Pending
- 2019-11-15 EP EP19817519.2A patent/EP3880210A1/en active Pending
- 2019-11-15 SG SG11202104499RA patent/SG11202104499RA/en unknown
- 2019-11-15 WO PCT/US2019/061626 patent/WO2020102628A1/en active Application Filing
- 2019-11-15 US US16/684,874 patent/US20200155578A1/en active Pending
-
2021
- 2021-05-02 IL IL282842A patent/IL282842A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020102628A1 (en) | 2020-05-22 |
MX2021005776A (es) | 2021-07-02 |
IL282842A (en) | 2021-06-30 |
CA3117983A1 (en) | 2020-05-22 |
TW202031265A (zh) | 2020-09-01 |
KR20210091139A (ko) | 2021-07-21 |
JP2022507528A (ja) | 2022-01-18 |
EP3880210A1 (en) | 2021-09-22 |
CN113015531A (zh) | 2021-06-22 |
AU2019379806A1 (en) | 2021-05-27 |
US20200155578A1 (en) | 2020-05-21 |
SG11202104499RA (en) | 2021-05-28 |
BR112021009353A2 (pt) | 2021-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017002939A1 (es) | Composiciones farmacéuticas tópicas | |
CO2018010748A2 (es) | Agentes antivirales contra la hepatitis b | |
UY37998A (es) | Agentes antivirales contra la hepatitis b | |
MX2019012676A (es) | Derivados de 2-aminoquinolina. | |
EA202090495A1 (ru) | Производные 6-амино-7,9-дигидро-8h-пурин-8-она в качестве иммуностимулирующих агонистов toll-подобного рецептора 7 (tlr7) | |
CL2019001685A1 (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares. | |
CO2020002980A2 (es) | Agentes antivirales contra la hepatitis b. | |
CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
BR112018070852A2 (pt) | composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas | |
CL2020000747A1 (es) | Formulaciones de niraparib. | |
CL2020001495A1 (es) | Composiciones y método para el tratamiento de enfermedades metabólicas | |
CL2019001586A1 (es) | Insulina que contiene composiciones farmacéuticas. | |
CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
AR106364A1 (es) | Derivados de insulina y sus usos médicos | |
CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
CO2022018636A2 (es) | Moduladores de il-17a | |
PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
PE20210116A1 (es) | Administracion oral de analogos del peptido glp-1 | |
CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
ECSP22040362A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
UY38473A (es) | Formulaciones farmacéuticas para una administración subcutánea | |
PE20211199A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
BR112017015613A2 (pt) | gel intestinal de levodopa e carbidopa e métodos de utilização |